MEDIUM confidence: 100% data completeness, but the composite (55) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $26.0B— | $26.3B+1.3% | $28.2B+7.1% | $33.4B+18.6% | $36.7B+9.9% |
| EPS (dil.) | $10.28— | $12.11+17.8% | $12.49+3.1% | $7.56-39.5% | $14.23+88.2% |
| Free Cash Flow | $8.4B— | $8.8B+4.8% | $7.4B-16.2% | $10.4B+41.2% | $8.1B-22.1% |
| Gross Margin | 75.2% | 75.7%+0.5pp | 70.1%-5.5pp | 61.5%-8.6pp | 70.8%+9.3pp |
| Operating Margin | 29.4% | 36.3%+6.9pp | 28.0%-8.3pp | 21.7%-6.3pp | 29.1%+7.3pp |
| Net Margin | 22.7% | 24.9%+2.2pp | 23.8%-1.1pp | 12.2%-11.6pp | 21.0%+8.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 3.9%/yr (revenue basis).
Base free cash flow $8.6B (avg FY2023–FY2025; latest year $8.1B) · equity value $253.7B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$2.9M over 180 days (0 open-market buys, 5 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Avg target $409 (last qtr, 26 analysts) → $419 (last mo, 8) (+2.5%).
Buy-rated share 41% → 35% over ~3 months (-6pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $5.62 | $6.29 | +11.9% |
| Apr 2026 | $4.77 | $5.15 | +8.0% |
| Feb 2026 | $4.73 | $5.29 | +11.8% |
| Nov 2025 | $5.02 | $5.64 | +12.4% |
| Aug 2025 | $5.28 | $6.02 | +14.0% |
| May 2025 | $4.27 | $4.90 | +14.8% |
| Feb 2025 | $5.04 | $5.31 | +5.4% |
| Oct 2024 | $5.11 | $5.58 | +9.2% |
The QScore of 55 for Amgen Inc. suggests a neutral outlook, driven by strong momentum and profitability scores of 65, indicating the stock exhibits strong price appreciation and high returns on equity near 90%. However, this is offset by lower scores in value and growth, with the stock trading at a premium as reflected in its P/E of 28.9 and P/B of 21.7. The long-term and short-term scores are relatively aligned, with only a 4-point difference, suggesting a consistent view across different time horizons.